Trends at the FDA

It's never too early to identify trends, and what better place to look than the FDA? The environment at the world's premier regulatory agency can have a significant impact the U.S. as well as the world markets, so it's always wise to keep an eye on happenings at the FDA. In that vein, here's an early look at four FDA trends we've identified so far this year. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.